Compare · DRS vs TMO
DRS vs TMO
Side-by-side comparison of Leonardo DRS Inc. (DRS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRS and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $177.93B, about 16.5x DRS ($10.81B).
- Over the past year, DRS is up 1.0% and TMO is up 14.2% - TMO leads by 13.2 points.
- DRS has been more active in the news (11 items in the past 4 weeks vs 9 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 12 for DRS).
- Company
- Leonardo DRS Inc.
- Thermo Fisher Scientific Inc
- Price
- $40.62+2.91%
- $479.36+2.79%
- Market cap
- $10.81B
- $177.93B
- 1M return
- -8.80%
- -2.51%
- 1Y return
- +1.04%
- +14.23%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 9
- Recent ratings
- 12
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest DRS
- Leonardo DRS Introduces Rugged 2kVA UPS for Mission-Critical Power Protection in Harsh Shipboard Environments
- AI-Driven Video Intelligence and RF-Powered Detection Moving to the Front Line of Military Modernization
- Leonardo DRS Launches New Maritime Counter-UAS Capability to Defeat Aerial Unmanned Threats at Sea
- SEC Form 4 filed by Dorfman Mark
- SEC Form 4 filed by Morrow Pamela
- SEC Form 4 filed by Rinsky Jason
- SEC Form 4 filed by Wallace Sally
- SEC Form 4 filed by Dippold Michael
- SEC Form 4 filed by Baylouny John
- The Pentagon Wants 200,000 Autonomous Systems. A Latin American Government Just Signed Its First Defense Order. And a Nasdaq Defense Tech Company Just Walked 580 Investors Through Its Three-Pillar AI Platform
Latest TMO
- President & COO Pettiti Gianluca sold $185,064 worth of shares (400 units at $462.66) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,051 units (SEC Form 4)
- Thermo Fisher Scientific to Host Investor Day
- Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026